SG Americas Securities LLC Purchases Shares of 24,031 Avanos Medical, Inc. (NYSE:AVNS)

SG Americas Securities LLC acquired a new position in Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 24,031 shares of the company's stock, valued at approximately $344,000. SG Americas Securities LLC owned approximately 0.05% of Avanos Medical as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of AVNS. T. Rowe Price Investment Management Inc. grew its holdings in shares of Avanos Medical by 27.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock worth $47,941,000 after acquiring an additional 644,267 shares during the period. Brown Advisory Inc. lifted its holdings in Avanos Medical by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock valued at $30,329,000 after acquiring an additional 204,218 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Avanos Medical by 43.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock worth $7,874,000 after purchasing an additional 148,902 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Avanos Medical by 189.8% during the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company's stock valued at $3,210,000 after purchasing an additional 132,063 shares during the period. Finally, Bridgeway Capital Management LLC grew its stake in shares of Avanos Medical by 87.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 273,251 shares of the company's stock valued at $4,350,000 after purchasing an additional 127,591 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Stock Performance

AVNS traded down $0.13 during trading on Thursday, hitting $12.15. The company's stock had a trading volume of 355,836 shares, compared to its average volume of 514,290. The business's 50 day simple moving average is $12.47 and its 200-day simple moving average is $14.44. The firm has a market cap of $561.58 million, a PE ratio of -1.45 and a beta of 1.14. Avanos Medical, Inc. has a one year low of $11.75 and a one year high of $25.36. The company has a quick ratio of 1.56, a current ratio of 2.57 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.19 by $0.07. The firm had revenue of $167.50 million during the quarter, compared to analyst estimates of $161.75 million. Avanos Medical had a positive return on equity of 6.26% and a negative net margin of 55.80%. Avanos Medical's revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business posted $0.22 EPS. As a group, sell-side analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.